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News
Pharmaceutical Resources Inc. selects VelQuest
solution to enable paperless laboratory opera-
tions in their quality & development organiza-
tions
Par Pharmaceuticals, a division of PRI, expects the Paperless
Laboratory to help expedite the launch of new Generic Pharma-
ceutical Products.
VelQuest Corporation, Hopkinton, MAö15 January 2002:
VelQuest, the innovator of Electronic Process Manage-
ment and Compliance Solution (ePMC
TM), and Phar-
maceutical Resources Inc. (PRI) (NYSE PRX), the
fastest growing stock in 2001 according to the NY Times
and leading US pharmaceutical company, announced
today that PRI has committed to implementing the
VelQuest’ s Compliance Electronic Notebook platform
as a key part of their overall quality, compliance and
data architecture plan.
` A critical challenge faced by generic pharmaceutical
companies is to be ® rst to market with generic drugs’ ,
said Robert Femia, Vice President of Scienti® c and
Regulatory Aå airs at Par Pharmaceuticals. ` Leveraging
our operations with VelQuest’ s ePMC Solution will allow
us to be more eæ cient and help to expedite our eå orts to
bring drugs to market’ .
To date, the typical process for preparing ANDA/NDA
submissions is paper-based and involves hours of review-
ing, retrieving and interpreting written data. Par Phar-
maceuticals has taken the initiative to implement an
electronic process management and compliance platform
using VelQuest’ s ePMC paperless solution. VelQuest’ s
ePMC solution with electronic notebooks will be de-
ployed in Par Pharmaceutical’ s quality & development
operations, providing an electronic paperless quality
solution for their data and documentation.
Pharmaceutical Resources has taken other initia-
tives in computer-based e¤ciency enhancements
through its recent acquisition of a controlling
interest in High Rapids Technologies, a software
¢rm that specializes in the implementation of
arti¢cial-intelligence-based applications within
speci¢c markets, such as the pharmaceutical in-
dustry. PRI’s selection of VelQuest’s Compliance
Electronic Notebook platform was identi¢ed as a
`best-in-class’ product to complement parallel ad-
vances in operational systems being made
through the High Rapids technology.
` We are very excited to complement PRI’ s investment in
High Rapids technology within their operations’ , said
Ken Rapp, President and CEO of VelQuest Corpora-
tion. ` Generic Pharmaceuticals are very important to
consumers and PRI continues to enjoy a leadership
position helping consumers with unique Generic alter-
natives in the pharmaceutical market’ .
VelQuest’ s ePMC platform is an innovative solution to
the fundamental problem that pharmaceutical labora-
tory records are frequently paper-based and laboratory
notebook documentation and data-auditing-related ac-
tivities can consume up to 70% of valuable human
resource. VelQuest’ s solution interacts with scientists in
real time and allows the capture of data directly from
human observations, electronic devices such as balances
and pH meters, and PC-controlled instruments. Vel-
Quest’ s solution was designed with compliance (cGMP,
GLP, 21 CFR Part 11) as the core functionality. The
company provides a comprehensive solution including
technology and services that enable pharmaceutical com-
panies to increase productivity and create an electronic
compliance platform.
Currently, VelQuest is deploying their ePMC solution at
several global pharmaceutical companies. The company
plans to continue to develop additional productivity and
compliance-oriented technology for the pharmaceutical
laboratory environment.
About VelQuest
VelQuest Corporation, headquartered in Hopkinton,
MA, the innovator of an electronic compliance platform
enabling the paperless laboratory using electronic note-
books, develops quality and compliance technology for
pharmaceutical development and quality operations.
VelQuest’ s ePMC solution provides a fully validated,
paperless approach to data acquisition, documentation,
storage and retrieval for use in new-product submissions,
product releases, stability testing, quality assurance and
management analysis. More information can be found at
www.velquest.com.
About Par Pharmaceuticals
Par Pharmaceutical Inc., located in Spring Valley, New
York, manufactures and distributes over 100 products
representing various dosage strengths of almost 50 drugs.
Par Pharmaceutical is dedicated to developing, manu-
facturing and marketing the highest-quality generic
pharmaceutical products for value-conscious healthcare
consumers. Our strength is the integration of leading
pharmaceutical technologies with quality and cost-
eæ cient manufacturing. For press releases and other
Company information, visit the website at http://
www.parpharm.com.
Certain statements herein constitute ` forward-looking
statements’ within the meaning of the Private Securities
Litigation Reform Act of 1995, including those concern-
ing management’ s expectations with respect to future
events or future ® nancial performance. Any such state-
ments that refer to either VelQuest’ s or PRI’ s anticipated
future results, product performance, or other non-histor-
ical facts are forward-looking and re¯ ect PRI’ s current
perspective of existing trends and information. These
Journal of Automated Methods & Management in Chemistry
Vol. 24, No. 1 (January–February 2002) pp. 27–28
Journal of Automated Methods & Management in Chemistry ISSN 1463± 9246 print/ISSN 1464± 5068 online # 2002 Taylor & Francis Ltd
http://www.tandf.co.uk/journals
DOI: 10.1080/14639240210132354
27statements involve risks and uncertainties that cannot be
predicted or quanti® ed; consequently, actual results may
diå er materially from those expressed or implied by such
forward looking statements.
For further information, please contact Ed Halpin, Tel:
+ 1(508) 497 3629, e-mail: edh@velquest.com
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